A second Phase 3 setback this year for an oral selective estrogen receptor degrader underscored how strongly trial outcomes may depend on patient biology. Coverage of Serena-4 indicated that camizestrant’s lack of efficacy in a broad first-line ER+ setting could mean sponsors will need to concentrate on ESR1-mutant populations to demonstrate a reliable benefit. The Serena-4 miss in HER2-negative, ER-positive breast cancer—using camizestrant with the CDK4/6 inhibitor palbociclib—further narrows the contexts where oral SERDs can convincingly compete against established endocrine strategies. In the same period, oncology attention also shifted toward several large lung cancer readouts, but the SERD trial outcome remains a direct signal for the oral estrogen-receptor class. For developers, the actionable implication is trial design: endpoint selection, biomarker enrichment criteria, and the probability of replicating efficacy signals outside narrower subgroups.